Evidence map›Paper›PMID 37463144›Full record

ArticlePloS one2023

Cleavage of the V-ATPase associated prorenin receptor is mediated by PACE4 and is essential for growth of prostate cancer cells.

Amro H Mohammad, Frédéric Couture, Isabelle Gamache, Owen Chen, Wissal El-Assaad, Nelly Abdel-Malak, Anna Kwiatkowska, William Muller, Robert Day, Jose G Teodoro

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 74% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Amro H MohammadGoodman Cancer Research Center, McGill University, Montréal, Québec, Canada.ORCID 0000-0001-7230-9195
Frédéric CoutureDepartment of Surgery/Urology, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.
Isabelle GamacheGoodman Cancer Research Center, McGill University, Montréal, Québec, Canada.
Owen ChenGoodman Cancer Research Center, McGill University, Montréal, Québec, Canada.
Wissal El-AssaadGoodman Cancer Research Center, McGill University, Montréal, Québec, Canada.
Nelly Abdel-MalakGoodman Cancer Research Center, McGill University, Montréal, Québec, Canada.
Anna KwiatkowskaDepartment of Surgery/Urology, Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Québec, Canada.ORCID 0000-0002-5659-3680
William MullerGoodman Cancer Research Center, McGill University, Montréal, Québec, Canada.
Robert DayPhenoSwitch Bioscience, Sherbrooke, Québec, Canada.
Jose G TeodoroGoodman Cancer Research Center, McGill University, Montréal, Québec, Canada.ORCID 0000-0002-3713-6839
McGill University · CAUniversité de Sherbrooke · CA

Funding

CIHR
6 · The paper itself

Abstract

Phosphatase and tensin homolog (PTEN) mutation is common in prostate cancer during progression to metastatic and castration resistant forms. We previously reported that loss of PTEN function in prostate cancer leads to increased expression and secretion of the Prorenin Receptor (PRR) and its soluble processed form, the soluble Prorenin Receptor (sPRR). PRR is an essential factor required for proper assembly and activity of the vacuolar-ATPase (V-ATPase). The V-ATPase is a rotary proton pump required for the acidification of intracellular vesicles including endosomes and lysosomes. Acidic vesicles are involved in a wide range of cancer related pathways such as receptor mediated endocytosis, autophagy, and cell signalling. Full-length PRR is cleaved at a conserved consensus motif (R-X-X-R↓) by a member of the proprotein convertase family to generate sPRR, and a smaller C-terminal fragment, designated M8.9. It is unclear which convertase processes PRR in prostate cancer cells and how processing affects V-ATPase activity. In the current study we show that PRR is predominantly cleaved by PACE4, a proprotein convertase that has been previously implicated in prostate cancer. We further demonstrate that PTEN controls PRR processing in mouse tissue and controls PACE4 expression in prostate cancer cells. Furthermore, we demonstrate that PACE4 cleavage of PRR is needed for efficient V-ATPase activity and prostate cancer cell growth. Overall, our data highlight the importance of PACE4-mediated PRR processing in normal physiology and prostate cancer tumorigenesis.

Indexed as

Prostatic NeoplasmsVacuolar Proton-Translocating ATPasesAnimalsHumansMaleMiceProprotein ConvertasesProrenin ReceptorReceptors, Cell SurfacePcsk6 protein, mouseProprotein ConvertasesProrenin ReceptorReceptors, Cell SurfaceVacuolar Proton-Translocating ATPases

Identifiers

PMID37463144
PMCPMC10353799
OpenAlexW4384664791

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.